This article is more than 5 years old. Information may no longer be current.
VIDEO: Negative ACCORD trial results reinforce standard of care for rectal cancer
Click Here to Manage Email Alerts
SAN FRANCISCO — Daniel Chang, MD, associate professor of radiation oncology at Stanford University, discusses the phase 3 ACCORD randomized trial data presented at the Gastrointestinal Cancers Symposium, which compared radiation with 5-fluorouracil (5-FU) vs. radiation with oxaliplatin and 5-FU in rectal cancer.
This turned out to be a negative trial, Chang said. “It showed no difference in terms of pathological complete response, disease-free survival, local control or overall survival by adding oxaliplatin. The one thing that has been consistent across all of these studies … [is] there was an increase in acute toxicity by adding oxaliplatin.”
These results confirm “what we already know, which is that oxaliplatin does contribute to toxicity but with no clear benefit in terms of pathological complete response or in terms of long term outcome,” he concluded. “We believe these results reinforce that long-course 45 Gy with capecitabine or 5-FU chemotherapy is the standard of care.”
Disclosure: Chang reports no relevant financial disclosures.